← Back to Clinical Trials
Recruiting NCT05521529

NCT05521529 Cushing's Syndrome Before and After Treatment (CORRECT)

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05521529
Status Recruiting
Phase
Sponsor University of Aarhus
Condition Cushing Syndrome
Study Type OBSERVATIONAL
Enrollment 20 participants
Start Date 2023-02-16
Primary Completion 2028-10

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type OBSERVATIONAL
Interventions
no intervention, as this is an observational study

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 20 participants in total. It began in 2023-02-16 with a primary completion date of 2028-10.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The purpose of this study is to prospectively study patients with Cushing's syndrome before and after treatment, with a special emphasis on physical function, quality of life, and circadian rhythms. The hypotheses are: * Cushing's syndrome negatively impacts health-related quality of life (HRQoL) and physical functioning * Cushing's syndrome is associated with altered circadian rhythms at the whole body level and in peripheral target tissues. * These complications partially reverse following disease control.

Eligibility Criteria

Inclusion Criteria: * New (≤ 2 months) diagnosis of Cushing's syndrome (CS) of endogenous etiology: * ACTH-dependent CS * ACTH-independent CS * Age \>18 years * Written informed consent Exclusion Criteria: * Active cancer * Iatrogenic or malignant cause of CS such as adrenocortical carcinoma * Chronic heart failure (New York Heart Association class IV) * Chronic kidney disease Chronic Kidney Disease stage ≥3 (eGFR \>30 ml/min) * Liver disease in the form of cirrhosis * Deemed unable to complete the study safely by investigator

Contact & Investigator

Central Contact

Simon Bøggild Hansen, MD

✉ simhan@clin.au.dk

📞 41111574

Principal Investigator

Jens Otto Lunde Jørgensen, Professor

STUDY DIRECTOR

AARHUS UNIVERSITY HOSPITAL, Medical Research Laboratory

Frequently Asked Questions

Who can join the NCT05521529 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Cushing Syndrome. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT05521529 currently recruiting?

Yes, NCT05521529 is actively recruiting participants. Contact the research team at simhan@clin.au.dk for enrollment information.

Where is the NCT05521529 trial being conducted?

This trial is being conducted at Aarhus, Denmark.

Who is sponsoring the NCT05521529 clinical trial?

NCT05521529 is sponsored by University of Aarhus. The principal investigator is Jens Otto Lunde Jørgensen, Professor at AARHUS UNIVERSITY HOSPITAL, Medical Research Laboratory. The trial plans to enroll 20 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology